ARVO Meeting Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Richer, S.
Right arrow Articles by Rudy, D
Right arrow Search for Related Content
PubMed
Right arrow Articles by Richer, S.
Right arrow Articles by Rudy, D
Invest Ophthalmol Vis Sci 2002;43: E-Abstract 2542.
© 2002 ARVO

The Lutein Antioxidant Supplementation Trial

SP Richer1, W Stiles1, L Statkute2, KY Pei1, J Frankowski1, J Nyland1, J Pulido3 and D Rudy4

1 Eye Clinic DVA Medical Center North Chicago IL
2 Cook County Hospital Chicago IL
3 Eye and Ear Infirmary UIC Chicago IL
4 Family Medicine FUHS/Chicago Medical School North Chicago IL

Commercial Relationships:   S.P. Richer, Kemin Foods, International, Des Moines, IA F; Nutraceutical Sciences Institute, Boynton Beach, FL F; Great Smokies Diagnostic Lab, Asheville, NC F; W. Stiles, None; L. Statkute, None; K.Y. Pei, None; J. Frankowski, None; J. Nyland, None; J. Pulido, None; D. Rudy, None.

Abstract

Purpose: We describe the results of the Lutein Antioxidant Supplementation Trial (LAST) for atrophic AMD. Methods: The design is prospective 12-month, placebo controlled, double blind, repeated measures and crossover of lutein vs. lutein/antioxidants on 90 mostly male veterans (74.7 yrs +/- 7.1 yrs) with atrophic AMD (CPT 365.2). A serial-visit clinical evaluation protocol previously described and validated with pilot case series data was used. (Richer et al, JAOA 1999; 70: 13-23). The ophthalmic component involved measurement of macular pigment optical density (MPOD), lens opacification rating, contrast sensitivity (CSF), low-luminance low-contrast visual acuity, glare recovery (GR) and activities of daily living associated with AMD (night driving / glare adaptation disturbance). Results: The 3 treatment groups (10 mg lutein, 10 mg lutein/antioxidants & placebo) were matched for these known confounders: age, years diagnosed with AMD, smoking/cardiovascular history, iris color, lens opacification and nutritional status/physical activity level. Average eye MPOD, as measured by heterochromic flicker photometry, increased on average by 0.09 log units (repeated factors ANOVA; p<0.05), or 50 % in both the lutein and lutein/antioxidant treatment groups by 12 months. There was statistically significant concurrent improvement in some measures of visual function including GR, CSF and dist/near visual acuity in both treatment groups. Crossover, double crossover and video-documentation of patient symptoms pre and post treatment, were consistent with objective data. Inclusion of multiple nutrients (besides lutein) appears to provide an added improvement to CSF. Conclusion: This short-term, small population prospective clinical trial agrees with studies suggesting AMD to be, in part, a nutrition responsive disorder. Reversibility of AMD symptoms has important biophysical, physiological and clinical implications. Larger and longer-term clinical trials must confirm these preliminary findings.

Keywords: 308 age-related macular degeneration • 462 macular pigment

© 2002, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. For permission to reproduce any part of this abstract, contact the ARVO Office at arvo{at}arvo.org.




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH